Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sclerotherapy vs Laser for Gingival Pyogenic Granuloma
NCT06639230Not yet recruiting
- Sponsor
- Assiut University
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of 10XB101 in lobular capillary hemangioma (PG) (2 arms), sponsored by Assiut University. Primary endpoints: Postoperative pain evaluated by NRS at 3 months, Recurrence rate at 3 months and 1 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
10XB101
03
Conditions
lobular capillary hemangioma (PG)
Beyond the preview
Go deeper on NCT06639230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639230.